Phaseline

Targets › ESR1

ESR1 (Estrogen receptor): drug programs, companies and trials

85 programs from 74 companies in 221 trials: 91 Phase 2, 53 Phase 3, 43 Phase 1, 34 Phase 4; Oncology, Genitourinary, Metabolic and endocrine; next expected readout Nov 2026.

Nuclear hormone receptor. The steroid hormones and their receptors are involved in the regulation of eukaryotic gene expression and affect cellular proliferation and differentiation in target tissues. (UniProt, P03372)

Open in Phaseline: the race on ESR1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
University of California, San FranciscoHormone Replacement Therapy (HRT)
Estrogen and progestin replacement
ESR1, ESR2, PGRPhase 4Adhesive Capsulitis of the ShoulderDec 2026
The AlfredBazedoxifene Acetate
Selective estrogen receptor modulator (SERM)
ESR1, ESR2Phase 4SchizophreniaDec 2026
Mackay Memorial HospitalConjugated equine estrogen (Premarin)
Estrogen receptor agonist (vaginal cream formulation)
ESR1, ESR2Phase 4Effect of DrugDec 2026
Insel Gruppe AG, University Hospital BernHormone Replacement Therapy (HRT)
Transdermal estradiol and oral micronized progesterone replacement
ESR1, ESR2, PGRPhase 4InsomniaJan 2027
University of California, IrvineEstring Vaginal Product
Estradiol released locally from a vaginal ring
ESR1, ESR2Phase 4Recurrent Urinary Tract InfectionJun 2027
Andrew ZakhariEstetrol
Estrogen receptor agonist
ESR2, ESR1Phase 4Ovarian EndometriomaJul 2027
University of Southern CaliforniaClomiphene Citrate
Estrogen receptor alpha modulator
ESR1Phase 4Infertility, FemaleJun 2028
Peking Union Medical College HospitalFemoston 2/10
Estradiol and dydrogesterone hormone replacement therapy
ESR1, PGRPhase 4Functional Hypothalamic AmenorrheaJun 2028
Penn State UniversityCombined Oral Contraceptive (COC) / Apri (Reclipsen)
Oral ethinyl estradiol-based contraceptive; estrogen receptor agonist
ESR1, ESR2, PGRPhase 4Other Disorders of Bone Development and GrowthDec 2028
Gangnam Severance HospitalTamoxifen
Estrogen receptor alpha modulator
ESR1Phase 4Breast CancerJan 2031
GE Healthcare18F Fluoroestradiol (ESTROTEP)
Estrogen receptor imaging agent
ESR1Phase 4Metastatic Breast Cancer–
Rachel MejiaClomiphene Citrate
Estrogen receptor alpha modulator
ESR1Phase 4Polycystic Ovary Syndrome–
Stemline TherapeuticsElacestrant
Estrogen receptor alpha degrader
ESR1Phase 3Breast Cancer; Metastatic Breast Cancer; Breast Neoplasms; Advanced Breast Cancer …Nov 2026
PfizerCMP 001
6-valent OspA-based Lyme disease vaccine
ESR1, OSPABPhase 3Lyme Disease; Advanced Malignancies; Lyme Borreliosis; Advanced Breast Cancer …Dec 2026
Pfizervepdegestrant
Estrogen receptor degrader (SERD)
ESR1Phase 3Breast Cancer; Healthy ParticipantsDec 2026
Eli LillyImlunestrant (LY3484356)
Selective estrogen receptor degrader (SERD)
ESR1Phase 3Breast Neoplasms; Breast Cancer; Anatomic Stage I Breast Cancer AJCC v8Dec 2026
AstraZenecaFulvestrant
Estrogen receptor alpha antagonist; Estrogen receptor degrader
ESR1Phase 3Breast Cancer; Locally Advanced or Metastatic Breast Cancer; Estrogen Receptor-positive Breast Cancer; Breast Cancer Metastatic …Dec 2026
National Cancer Institute (NCI)Tamoxifen Citrate
Estrogen receptor alpha modulator
ESR1Phase 3Breast Ductal Carcinoma In Situ; Breast Adenocarcinoma; Breast Atypical Hyperplasia; Breast Atypical Ductal HyperplasiaJan 2027
Andrea DeCensiTamoxifen
Estrogen receptor alpha modulator
ESR1Phase 3Carcinoma, Intraductal, Noninfiltrating; Breast CancerJan 2027
Eurofarma LaboratoriosEstradiol
Estrogen receptor alpha agonist
ESR1Phase 3Acne VulgarisFeb 2027
Fudan Universitytamoxifen
Estrogen receptor alpha modulator
ESR1Phase 3Ductal Carcinoma In Situ, DCIS; Pancreatic NeoplasmsFeb 2027
LeonaBioLasofoxifene
Estrogen receptor modulator
ESR2, ESR1Phase 3Metastatic Breast CancerApr 2027
AstraZenecaCamizestrant (AZD9833)
Estrogen receptor alpha degrader
ESR1Phase 3Breast Cancer, Early Breast Cancer; ER-Positive HER2-Negative Breast Cancer; Advanced Breast Cancer; Advanced ER-Positive HER2-Negative Breast Cancer …Apr 2027
RocheGiredestrant
Estrogen receptor alpha degrader
ESR1Phase 3Estrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast Cancer; Early Breast Cancer; Breast CancerJun 2027
RocheGiredestrant
Estrogen receptor alpha degrader
ESR1Phase 3Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer; Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer; Locally Advanced or Metastatic Breast Cancer; Early Breast Cancer …Jul 2027
Sarah WozneyConjugated Estrogens CSD
Estrogen receptor agonist
ESR1, ESR2Phase 3Pelvic Organ Prolapse (POP)Sep 2027
Olema PharmaceuticalsPalazestrant (OP-1250)
Complete Estrogen Receptor Antagonist
ESR1Phase 3Breast Cancer; Metastatic Breast CancerDec 2027
Jiangsu Simcere Pharmaceutical[14C] SIM0270
Selective estrogen receptor degrader (SERD)
ESR1Phase 3Locally Advanced or Metastatic Breast Cancer; Breast Cancer; Healthy Participants; Healthy Adult ParticipantsAug 2028
Assistance Publique - Hôpitaux de ParisEstrogens (ESTREVA® 0.1% gel or PROVAMES® 1 mg)
Estrogen receptor agonist
ESR1, ESR2Phase 3Gender DysphoriaJun 2029
University of VirginiaTamoxifen
Estrogen receptor alpha modulator
ESR1Phase 3Breast Cancer FemaleJun 2029
Azienda Ospedaliero-Universitaria Careggitamoxifen
Estrogen receptor alpha modulator
ESR1Phase 3Breast CancerMar 2030
NRG OncologyTamoxifen
Estrogen receptor alpha modulator
ESR1Phase 3Stage I Breast CancerApr 2031
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)Estrogens, Conjugated
Estrogen receptor agonist
ESR2, ESR1Phase 3Premature Ovarian InsufficiencyDec 2031
Karolinska InstitutetTamoxifen
Estrogen receptor alpha modulator
ESR1Phase 3Breast CancerAug 2036
Tokyo Women's Medical UniversityEndocrine therapy plus ovarian function suppression (OFS)
Estrogen receptor antagonism with ovarian suppression
ESR1Phase 3Breast CancerJan 2038
Sana'a UniversityClomiphene
Estrogen receptor alpha modulator
ESR1Phase 3Infertility Drugs–
Hatice Tukenmez KurnazEstriol
Estrogen receptor modulator
ESR2, ESR1Phase 3Pelvic Organ Prolapse–
Atossa Therapeutics(Z)-endoxifen
Selective estrogen receptor modulator (SERM)
ESR1Phase 2Breast NeoplasmsNov 2026
AHS Cancer Control AlbertaTamoxifen
Estrogen receptor alpha modulator
ESR1Phase 2Glioblastoma MultiformeDec 2026
Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB ChairRaloxifene
Estrogen receptor beta modulator; Estrogen receptor modulator
ESR2, ESR1Phase 2Breast Cancer; BPH (Benign Prostatic Hyperplasia); Brain TumorDec 2026
NovartisFulvestrant
Estrogen receptor alpha antagonist; Estrogen receptor degrader
ESR1Phase 2Advanced Breast Cancer; Breast CancerDec 2026
Tianjin Medical University Cancer Institute and HospitalToremifene
Estrogen receptor modulator
ESR2, ESR1Phase 2CANCERDec 2026
Centre de recherche du Centre hospitalier universitaire de Sherbrooke4FMFES-PET
Estrogen receptor (ER) imaging tracer; 18F-labeled fluoroestradiol analogue that binds to
ESR1Phase 2ER+ Breast CancerDec 2026
Azure BiotechLasofoxifene Tartrate (AZU-101)
Estrogen receptor modulator
ESR2, ESR1Phase 2Vulvo Vaginal Atrophy (VVA)Dec 2026
University of Southern Californiabazedoxifene / conjugated estrogens
Tissue selective estrogen complex (TSEC)
ESR1, ESR2Phase 2AtherosclerosisDec 2026
Roberta BrintonPhytoSERM
Phytoestrogen supplement containing genistein, daidzein, and S-equol
ESR1, ESR2Phase 2MenopauseJan 2027
Washington University School of MedicineTamoxifen
Estrogen receptor alpha modulator
ESR1Phase 2Breast CancerJan 2027
National Cancer Institute (NCI)Z-Endoxifen Hydrochloride
Estrogen receptor antagonist
ESR1Phase 2Recurrent Breast Carcinoma; HER2/Neu Positive; Breast Carcinoma In SituFeb 2027
Jose Pablo LeoneTamoxifen
Estrogen receptor alpha modulator
ESR1Phase 2Male Breast CancerApr 2027
National University Hospital, Singapore17 beta-Estradiol topical gel
Estrogen receptor agonist
ESR1Phase 2ArthralgiaApr 2027
UNC Lineberger Comprehensive Cancer Centertamoxifen
Estrogen receptor alpha modulator
ESR1Phase 2Breast CancerApr 2027
UNC Lineberger Comprehensive Cancer Centertoremifene
Estrogen receptor modulator
ESR2, ESR1Phase 2Breast CancerApr 2027
University of Kansas Medical CenterBazedoxifene and Conjugated Estrogens
Selective estrogen receptor modulator (SERM) plus estrogen hormone replacement therapy
ESR1, ESR2Phase 2Risk ReductionJul 2027
Abramson Cancer Center at Penn Medicine18F-Fluoroestradiol
Fluorine-18 labeled estrogen analog for PET imaging of estrogen receptor activity
ESR1Phase 2Uterine CancerAug 2027
National Cancer Institute (NCI)Acolbifene Hydrochloride
Selective estrogen receptor modulator (SERM)
ESR1Phase 2Breast Atypical HyperplasiaAug 2027
Nutrindo Ideais Research CenterOESTROGEL
Transdermal estradiol; estrogen receptor agonist
ESR1, ESR2Phase 2MenopauseOct 2027
Nutrindo Ideais Research CenterPENTRAVAN
Transdermal estradiol delivery system; estrogen receptor agonist
ESR1, ESR2Phase 2MenopauseOct 2027
Shanghai Best-Link BioscienceBL0175
Estrogen receptor downregulator delivered via nano-medicine formulation
ESR1Phase 2Breast Cancer (Locally Advanced or Metastatic); Breast CancerOct 2027
Institut Cancerologie de l'OuestTamoxifen
Estrogen receptor alpha modulator
ESR1Phase 2Breast Cancer; Ductal Carcinoma in SituJan 2028
University of UtahClomiphene Citrate
Estrogen receptor alpha modulator
ESR1Phase 2Rotator Cuff TearsJul 2028
Rutgers, The State University of New JerseyTamoxifen
Estrogen receptor alpha modulator
ESR1Phase 2High Risk for Invasive Breast CancerJul 2028
Medical College of WisconsinTamoxifen
Estrogen receptor alpha modulator
ESR1Phase 2Breast CancerSep 2028
QuantumLeap Healthcare CollaborativeZ-endoxifen
Estrogen receptor antagonist (active metabolite of tamoxifen)
ESR1Phase 2Ductal Carcinoma in SituNov 2028
Roswell Park Cancer InstituteTamoxifen
Estrogen receptor alpha modulator
ESR1Phase 2Anatomic Stage III Breast Cancer AJCC v8Nov 2028
Seoul National University HospitalTamoxifen
Estrogen receptor alpha modulator
ESR1Phase 2Premenopausal Breast CancerDec 2028
Fred Hutchinson Cancer CenterTransdermal Estrogen
Estrogen receptor agonist
ESR1, ESR2Phase 2Castration-Sensitive Prostate AdenocarcinomaJun 2029
Università Vita-Salute San Raffaele16-alpha-18F-fluoro-17-beta-estradiol (FES)
Radiolabeled estrogen analog binding to estrogen receptor alpha (functionally active ER)
ESR1Phase 2Breast Cancer FemaleJun 2029
PfizerPF-07850327 / ARV-471 / vepdegestrant
PROTAC ER degrader
ESR1Phase 2Locally Advanced or Metastatic ER+ HER2- Breast CancerAug 2029
University of Virginiatransdermal 17β-E2 with cyclic progestin
Estrogen receptor agonist with cyclic progestin
ESR1, ESR2, PGRPhase 2Bone StrengthDec 2029
Memorial Sloan Kettering Cancer Centertamoxifen
Estrogen receptor alpha modulator
ESR1Phase 2Breast CancerMar 2030
University Health Network, TorontoTamoxifen
Estrogen receptor alpha modulator
ESR1Phase 2HypogonadismOct 2030
University of WashingtonF-18 16 Alpha-Fluoroestradiol
Estrogen receptor imaging agent
ESR1Phase 2Estrogen Receptor PositiveApr 2041
Northwestern UniversityAfimoxifene
Estrogen receptor modulator; Estrogen-related receptor gamma antagonist
ESR2, ESR1, ESRRGPhase 2Cancer Survivor–
City of Hope Medical CenterF-18 16 Alpha-Fluoroestradiol
Fluorine-18 labeled estrogen receptor ligand for imaging
ESR1Phase 2Anatomic Stage IV Breast Cancer AJCC v8–
Shayna Showalter, MDtamoxifen
Estrogen receptor alpha modulator
ESR1Phase 2Breast Cancer Female–
H. Lee Moffitt Cancer Center and Research InstituteDC1 native/mutated ESR1
Dendritic cell vaccine targeting native and mutated ESR1 epitopes
ESR1Phase 1Breast Cancer Metastatic Breast CancerNov 2026
Anthony Joshua, FRACPTamoxifen
Estrogen receptor alpha modulator
ESR1Phase 1Ovarian CancerJan 2027
University of PennsylvaniaEstrogens, Conjugated
Estrogen receptor agonist
ESR2, ESR1Phase 1Ischemia Reperfusion InjuryJan 2027
Tianjin Medical University Cancer Institute and Hospitalendocrine therapy
estrogen receptor antagonist or degrader (tamoxifen, aromatase inhibitors, or fulvestrant)
ESR1Phase 1Breast CancerFeb 2027
Corium InnovationsEstradiol
Estrogen receptor alpha agonist
ESR1Phase 1Healthy Female Participants; Menopause; Perimenopause; Infertilities …May 2027
Herbert LyerlyESR1 peptide vaccine
ESR1-derived peptide vaccine with Montanide adjuvant and GM-CSF
ESR1Phase 1Breast CancerAug 2027
University of NebraskaTamoxifen
Estrogen receptor alpha modulator
ESR1Phase 1Pancreatic CystNov 2028
St. Joseph's Healthcare HamiltonDuavive (conjugated estrogens/bazedoxifene)
Estrogen receptor agonist with selective estrogen receptor modulator component
ESR1, ESR2Phase 1Menopause–
Kashiv BioSciencesKSHN001034
Selective estrogen receptor degrader (SERD); fulvestrant equivalent
ESR1Phase 1Healthy Postmenopausal Women–
University of OxfordMenopausal hormone therapy (systemic, oestrogen-containing)
Oestrogen receptor agonist
ESR1, ESR2Phase 1Menopause–

Conditions

Breast Cancer (47) Menopause (12) Metastatic Breast Cancer (11) Breast Neoplasms (6) Advanced Breast Cancer (6) Recurrent Urinary Tract Infection (5) Turner Syndrome (4) Breast Cancer Female (3) ER-Positive HER2-Negative Breast Cancer (3) Ductal Carcinoma in Situ (3) Locally Advanced or Metastatic Breast Cancer (3) ER+ Breast Cancer (3)

Modalities

small molecule (73), mixed (4), other (3), protein or peptide (1)

Companies

National Cancer Institute (NCI) (3) Pfizer (3) AstraZeneca (2) University of Southern California (2) Roche (2) Tianjin Medical University Cancer Institute and Hospital (2) University of Virginia (2) Nutrindo Ideais Research Center (2) UNC Lineberger Comprehensive Cancer Center (2) Rutgers, The State University of New Jersey (1) Abramson Cancer Center at Penn Medicine (1) Eurofarma Laboratorios (1) Shayna Showalter, MD (1) Eli Lilly (1) Sarah Wozney (1) Medical College of Wisconsin (1) QuantumLeap Healthcare Collaborative (1) Shanghai Best-Link Bioscience (1) Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair (1) Università Vita-Salute San Raffaele (1)

Related targets

ESR2 (27) PGR (5) OSPAB (1) ESRRG (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.